藥品參考
Brentuximab vedotin
Brentuximab vedotin is a medicine in the class oncology. It is used for b-cell lymphoma.
- 藥物類別: Oncology
- 用途: b-cell lymphoma
最後更新 來源: US FDA label, EMA SmPC
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01FX05
- 常見劑型
- 注射劑
- 常見規格
- 50 mg/10.5 ml
- 已知交互作用
- 24 (禁忌併用: 1 · 嚴重: 1 · 中度: 13 · 輕微: 9)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
CD30-directed antibody-drug conjugate: a chimeric IgG1 linked to the microtubule-disrupting agent MMAE. After binding CD30-expressing cells and internalization, MMAE is released and binds tubulin, causing cell cycle arrest and apoptosis.
成人常用劑量（仿單摘要）
Monotherapy for adults: 1.8 mg/kg up to a maximum of 180 mg, intravenous infusion over 30 minutes, every 3 weeks
懷孕與哺乳
- 懷孕
- Unsafe Antibody-drug conjugate (cytotoxic MMAE): can cause fetal harm. Avoid in pregnancy. Women: effective contraception during treatment and for 2 months after; men with female partners: 4 months.
- 哺乳
- Unsafe No human milk data. Avoid breastfeeding during treatment because of possible serious infant harm (low blood counts, nerve or gut toxicity).
已通報的副作用
- Peripheral neuropathy
- Nausea
- Fatigue
- Musculoskeletal pain
- Constipation
- Diarrhea
黑框警語
- JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving ADCETRIS.
禁忌症
- Concomitant use with bleomycin due to pulmonary toxicity
哪些人需要特別留意
- Peripheral neuropathy is cumulative, predominantly sensory; monitor and modify dose, delay or discontinue.
- Anaphylaxis and infusion reactions: monitor during infusion; permanently discontinue for anaphylaxis.
- Hematologic toxicities including fatal febrile neutropenia; monitor CBC before each dose; G-CSF primary prophylaxis in combination regimens.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (24)
- Bleomycin + Brentuximab vedotin Contraindicated
- Brentuximab vedotin + Siponimod Major
- Apalutamide + Brentuximab vedotin Moderate
- Brentuximab vedotin + Clarithromycin Moderate
- Brentuximab vedotin + Imatinib Moderate
- Brentuximab vedotin + Isoniazid Moderate
- Brentuximab vedotin + Itraconazole Moderate
- Brentuximab vedotin + Ketoconazole Moderate
- Brentuximab vedotin + Mifepristone Moderate
- Brentuximab vedotin + Posaconazole Moderate
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Brentuximab vedotin 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
在網頁版免費試用 Pro+ 14 天，無需信用卡。
同類別的其他藥品
常見問題
What is Brentuximab vedotin used for?
Brentuximab vedotin is a medicine in the class oncology. It is used for B-cell lymphoma, Hodgkin lymphoma, Lymphoma.
What side effects have been reported with Brentuximab vedotin?
Peripheral neuropathy, Nausea, Fatigue, Musculoskeletal pain, Constipation, Diarrhea. Serious warning: JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving ADCETRIS.
Can Brentuximab vedotin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Antibody-drug conjugate (cytotoxic MMAE): can cause fetal harm. Avoid in pregnancy. Women: effective contraception during treatment and for 2 months after; men with female partners: 4 months. Breastfeeding: Unsafe. No human milk data. Avoid breastfeeding during treatment because of possible serious infant harm (low blood counts, nerve or gut toxicity).
What does Brentuximab vedotin interact with?
MediHelp lists 24 known interactions for Brentuximab vedotin. Contraindicated: 1 · Major: 1 · Moderate: 13 · Minor: 9. The most serious include Bleomycin, Siponimod, Apalutamide.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
